Pfizer has said it will shed staff and cut its operating costs by around $3.5 billion, as it faces a shortfall in COVID-19 vaccine and treatment sales, with revenues now e
In its second pipeline-boosting deal in two days, Sanofi has pledged €469 million (around $490 million) upfront for rights to an anti-TL1A therapy being developed by Teva
Roche is reported to be in the final stages of negotiating a deal with Roivant for an inflammatory bowel disease (IBD) candidate that could be worth up to $7 billion, acco
AstraZeneca has taken a look at the competition emerging in the market for inflammatory bowel disease (IBD) therapies, and decided to shelve a project that had advanced in
More than three years after it was first rejected by the FDA, Takeda's subcutaneous (SC) formulation of Entyvio has been resubmitted as a maintenance therapy for ulcerativ
Merck & Co has reached an agreement to buy Prometheus Biosciences in a $200-per-share cash transaction that values the San Diego-based biotech at $10.8 billion.
Hospital staff in the UK have developed and piloted an app that can help patients monitor their progress to recovery after surgeries and feed information back to their car
It’s 2024, and in most clinical trials, data is still being moved from the EHR to the EDC manually – with employees reading data from one screen and typing it onto another.